Intravenous brexanolone for postpartum depression: what it is, how well does it work, and will it be used?
Postpartum depression is considered to be a subtype of major depressive disorder that occurs in approximately 10-20% of mothers worldwide. However, in actuality, these numbers are likely underreported due to minimization and the stigma of mental illness. Until recently, there were no approved medica...
Saved in:
Main Authors: | Justin Faden (Author), Leslie Citrome (Author) |
---|---|
Format: | Book |
Published: |
SAGE Publishing,
2020-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Brexanolone: panacea for postpartum depression? Reply to: 'Intravenous brexanolone for postpartum depression: what it is, how well does it work, and will it be used?'
by: Ajay Kumar Shukla, et al.
Published: (2021) -
Safety of Brexanolone in Adults with Postpartum Depression: Postmarketing Surveillance Data
by: Svetlana Garafola, et al.
Published: (2023) -
Patient-reported perceptions of brexanolone in the treatment of postpartum depression: A qualitative analysis
by: Aaron Salwan, PharmD, MPH, BCPP, et al.
Published: (2023) -
Asenapine: an atypical antipsychotic with atypical formulations
by: Meghan Musselman, et al.
Published: (2021) -
Positive postpartum well‐being: What works for women
by: Susan Hannon, et al.
Published: (2022)